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Strengths and limitations of this study
 ► To our knowledge, this is the first comprehensive 
systematic review that will address the use of oral 
antibiotics for acne and their contribution to antimi-
crobial resistance.
 ► Screening, data extraction and quality assessment 
will be undertaken independently by three medically 
qualified researchers with training in systematic re-
view methodology, thereby ensuring scientific rigour, 
transparency and repeatability.
 ► There are no date or language restrictions; howev-
er, this systematic review will not examine the grey 
literature.
AbStrACt
Introduction Antimicrobial resistance (AMR) is a global 
health emergency. Acne vulgaris is a highly prevalent 
condition and the dominant role antibiotics play in its 
treatment is a major concern. Antibiotics are widely used 
in the treatment of acne predominantly for their anti- 
inflammatory effect, hence their use in acne may not be 
optimal. Tetracyclines and macrolides are the two most 
common oral antibiotic classes prescribed, and their 
average use can extend from a few months to several 
years of intermittent or continuous use. The overall aim of 
this systematic review is to elucidate what is known about 
oral antibiotics for acne contributing to antibiotic treatment 
failure and AMR.
Methods and analysis A systematic review will be 
conducted to address the question: What is the existing 
evidence that long- term oral antibiotics used to treat acne 
in those over 8 years of age contribute towards antibiotic 
treatment failure or other outcomes suggestive of the 
impact of AMR? We will search the following databases: 
Embase, MEDLINE, the Cochrane Library and Web of 
Science. Search terms will be developed in collaboration 
with a librarian by identifying keywords from relevant 
articles and by undertaking pilot searches. Randomised 
controlled trials, cohort and case- controlled studies 
conducted in any healthcare setting and published in any 
language will be included. The searches will be re- run 
prior to final analyses to capture the recent literature. 
The Cochrane tool for bias assessment in randomised 
trials and ROBINS- I for the assessment of bias in non- 
randomised studies will be used to assess the risk of bias 
of included studies. GRADE will be used to make an overall 
assessment of the quality of evidence. A meta- analysis will 
be undertaken of the outcome measures if the individual 
studies are sufficiently homogeneous. If a meta- analysis is 
not possible, a qualitative assessment will be presented as 
a narrative review.
Ethics and dissemination Ethical approval is not 
required for this systematic- review. The results will be 
published in a peer- reviewed journal and any deviations 
from the protocol will be clearly documented in the 
published manuscript of the full systematic- review.
PrOSPErO registration number CRD42019121738.
IntrOduCtIOn
The future effectiveness of antibiotics is in 
jeopardy with the WHO declaring the threat 
of antimicrobial resistance (AMR) as a most 
urgent crisis.1 Future deaths from infections 
as a result of AMR without any intervention is 
estimated at 10 million per year and by 2050 
the cost of AMR could reach 100 trillion US 
Dollars.2
Topical and oral antibiotics are commonly 
prescribed for the treatment of acne vulgaris, 
a chronic skin disorder with onset predomi-
nantly in adolescence. Given the psychosocial 
consequences and the potential for perma-
nent disfigurement with scarring, it is imper-
ative that people with acne receive effective 
treatment.3 4 Prevalence studies show that 
80% to 100% of teenagers have acne and that 
20% are moderately- to- severely affected. The 
high prevalence means that both topical and 
oral antibiotics are used in a large proportion 
of the adolescent population and for vari-
able durations ranging from 6 weeks to many 
months, and in some cases, several years.5 6 
Differences between international guidelines 
regarding duration of treatment is one of the 
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reasons that antibiotics for acne are used for significantly 
longer than recommended as there is uncertainty about 
the optimal duration of treatment.6–11 Tetracyclines and 
macrolides are the two of the most common oral antibi-
otic classes prescribed for acne with varying durations of 
average use depending on treatment setting and between 
different countries.6 12
The overuse of antibiotics is a known cause of AMR 
as repeated and sustained exposure allows microbes to 
develop mechanisms to avoid the effects of the drugs 
designed to treat them and allows selection in favour of 
bystander or commensal bacteria with resistance subse-
quently causing invasive infection. Acne is aetiologically 
multifactorial and we already know that some strains of 
Cutibacterium acnes (formally Propionibacterium acnes), 
the bacteria pathophysiologically associated with acne, 
are now resistant to commonly used antibiotics in acne, 
making their initial use as anti- microbial agents futile.13 14 
However, we do not know how these long- term antibiotics 
for acne may attenuate microbiota elsewhere at other 
body sites and the ability of other bacteria at other infec-
tive sites to withstand the effect of antibiotics. Despite 
this, the anti- inflammatory effect and proven efficacy of 
antibiotics in treating acne ensures their continued use,15 
although their effects may not be sustained. Considering 
the relationship between long- term exposure to antibi-
otics and AMR, this practice may not be optimal.
The effects long- term antibiotics for acne have on future 
infections caused by resistant organisms, subsequent anti-
biotic treatment failure or the rate of infections (or any 
other measures which may indicate antimicrobial resis-
tance) and how long any effect may last, is not yet known 
and has not been systematically reviewed in the literature 
before. While antibiotic stewardship programmes have 
been shown to be effective16 in other settings, to ensure 
their successful execution, robust evidence must be 
generated to show that using antibiotics in the treatment 
of acne has important implications for future infective 
episodes and resistance sequelae. Until there is evidence 
of how the use of oral antibiotics for acne may cause AMR, 
changing current practice will be challenging.17
Given the global health emergency of AMR and 
the dominant role antibiotics play in the treatment of 
acne—a highly prevalent and ubiquitous skin condition 
worldwide, there is a clearly defined evidence gap which 
needs to be urgently addressed.18 This systematic review 
aims to establish what is already known about resistance 
sequelae for those with acne who are treated with long- 
term topical or oral antibiotics.19
MEthOdS And AnAlySIS
literature search strategy
We will search the following databases; Embase, 
MEDLINE, the Cochrane Library and Web of Science. 
We will develop the search terms by identifying keywords 
from relevant articles and by undertaking pilot searches 
to identify index or MedicalSubject Heading (MeSH) 
terms. We will modify the search terms according to each 
database, for example, the MeSH terms in MEDLINE and 
Emtree terms in Embase. Searches will be undertaken 
by the lead author who has medical and search training 
in collaboration with a librarian. Search strategies will 
be reviewed by all authors. The searches will be kept as 
broad as possible, for example, by using the ‘explode’ 
function on the Ovid platform to maximise the number 
of relevant articles. The search strategy is available to view 
in the accompanying supplement (online supplementary 
file 1). Searches were undertaken on the 19th of July 2019 
and date back to inception of the databases.
Eligibility criteria
Inclusion criteria
To address the question, the following inclusion criteria 
will apply:
 ► A study population including participants aged over 
the age of 8 in any healthcare setting with acne 
vulgaris.
 ► Original studies will be eligible for assessment for 
inclusion if they address the specific research question.
 ► Randomised controlled trials (of any trial design).
 ► Observational studies limited to cohort and case- 
control studies.
 ► We will include conference abstracts if the full paper 
is unpublished and can be obtained from the authors.
Exclusion criteria
 ► Ecological studies and studies that do not assess 
temporality such as case- series and case reports.
 ► We will exclude unpublished studies, ongoing studies 
and the grey literature.
 ► In addition, studies which only look at antimicrobial 
resistance in Propionibacterium acnes or Cutibacterium 
acnes.
 ► Studies including people who are under the age of 8 
exclusively will be excluded. The age of 8 was chosen 
as acne vulgaris is unlikely to present in younger chil-
dren and in addition, tetracyclines are not recom-
mended in younger children—the British National 
Formulary recommends tetracyclines are given to 
children aged 12 years and above.
 ► Studies including people who are treated with antibi-
otics for other acne subtypes, for example, hidrade-
nitis suppurativa or drug- induced acne.
Exposure
At least 28 days of continuous (daily doses) oral antibi-
otics for acne vulgaris, the duration helping to ensure 
treatment is not targeted at an acute infective episode 
and, in addition, 28 days is the minimum duration a 
prescription will be issued for an antibiotic treatment of 
acne. The exposure is likely to include commonly used 
antibiotic classes—tetracyclines, macrolides and dihy-
drofolate reductase inhibitors, however there will be no 
limits placed on the antibiotic class used to treat acne. We 
have excluded the use of topical antibiotics are these are 
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less likely to have an effect at sites other than the skin to 
where they are applied.
Comparator
No exposure to long- term oral antibiotics within an acne 
population or within a general population.
Outcome
The primary outcome is antibiotic treatment failure 
or any infection caused by a resistant organism. The 
secondary outcome is the detection of resistant organisms 
without a clinical infection, rate of infection or changes 
to the microbiota profile, for example, with the coloni-
sation of resistant microbiota without a clinical infection 
or different microbiota in a sampled site compared with 
baseline prior to having received a long- term antibiotic 
for acne. Any measure (including proxy measures) will 
be included, for example, laboratory measures (such as 
an elevated C- reactive protein or positive culture in the 
case of an infection at any body site), patient observations 
(such as an elevated temperature and/or pulse rate which 
may indicate an infective process) or proxy measures 
that may have been used in epidemiological studies, for 
example, difficult to treat infections which may indicate 
a resistant infection. Each outcome will be assessed sepa-
rately. The outcome can occur at any time point after at 
least 28 days of continuous oral antibiotic exposure for 
acne; we will stratify according to the length of follow- up, 
for example, up to 6 months, 6 months to 1 year, 1 year to 
2 years, and so on.
Potential confounding variables/effect modifiers
Confounding factors that may be considered by studies 
investigating treatment failure or AMR as a result of long- 
term antibiotics for acne are: age, sex, socioeconomic 
status, treatment adherence, medical conditions such 
as primary immunodeficiency, diabetes, asthma, cancer 
requiring immunosuppressive medication, recent hospi-
talisation within the last 6 months, repeated admissions 
to hospital, any recurrent infections, other prescribed 
medication in particular immunosuppressive therapy 
including oral corticosteroids, smoking, alcohol use and 
ethnicity. We will also explore effect modification. The 
inclusion of these confounding factors will be acknowl-
edged in the bias assessment of each study along with a 
statement of the direction and magnitude of bias their 
omission may be associated with.
Eligibility assessment and data extraction
Phase 1
Covidence, an online literature review data management 
programme, will be used to facilitate the systematic review 
process inclusive of title and abstract screening, full paper 
retrieval and storage and decisions on which papers to 
include at full text review. In the first phase, all titles 
and abstracts will be uploaded to Covidence. Duplicates 
will then be removed by the lead reviewer (KB). Three 
reviewers (KB, L- YL and JB) will then independently 
screen the search results based on title and abstract. Each 
title/abstract will require two votes. Consensus will be 
achieved on the number of titles and abstracts to include 
in the full study review. Any disputes will be resolved by 
the involvement of a fourth reviewer (SML).
Phase 2
Full text papers will be assessed independently by the 
reviewer pairs using a standardised data extraction form. 
The extraction tool will be piloted using the first three 
included records, after which modifications may be made 
following discussion with other members of the review 
team. The quality of the studies will be scored using assess-
ment tools and free text explanations for the score given 
will be included on the score sheet. Any disagreements 
will be discussed by the three reviewers (KB, L- YL and 
JB) and in instances of disagreement, a fourth reviewer 
(SML) will make a final decision. If ambiguity still remains 
after the full text is obtained, the study authors will be 
contacted for further clarification.
Data items
Three data domains will be extracted:
Data relating to study design
Author, country, specific study design, the year the study 
was conducted or the years over which the data were 
collected. Healthcare setting, the number of study partici-
pants, the ages of the participants and the gender balance 
will be collected for the whole population under study, 
including the comparator group. If the study is a trial, 
then specifics of the study design such as randomisation, 
allocation concealment and blinding will be noted.
Data relating to exposure
The dose, frequency and antibiotic used, the median/
mean length of treatment of acne with the antibiotic, the 
definition of long- term treatment with antibiotics used in 
the study, the number of participants exposed to antibi-
otics and if multiple courses are prescribed, the length 
of time between antibiotic courses and the intervention 
applied to comparators.
Data relating to outcomes
The measure of antibiotic treatment failure or AMR 
and the degree of antibiotic treatment failure or AMR, 
for example, repeat course required, hospitalisation or 
death. The length of follow- up will be stratified.
Study quality assessment
Each study will be critically appraised by reviewers. The 
Cochrane tool for bias assessment in randomised studies 
and the ROBINS- I tool for the assessment of bias in non- 
randomised studies will be used to assess the risk of bias 
in included studies.20–22 GRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) 
will be used to make an overall assessment of the quality 
of evidence.22 Pairs of reviewers will make independent 
assessments of the risk of bias. Markers of bias depending 
on study design included in the aforementioned scoring 
 on A









pen: first published as 10.1136/bm




4 Bhate K, et al. BMJ Open 2020;10:e033662. doi:10.1136/bmjopen-2019-033662
Open access 
tools will include factors such as the method of partici-
pant selection, follow- up, randomisation, adjustment for 
confounding and measurement error of exposures or 
outcomes. If a proportion of studies have a high risk of 
bias found using the scoring tool we will do a sensitivity 
analysis excluding them.
data synthesis/statistical analysis
We will analyse interventional and observational studies 
separately. If there is homogeneity across studies and a 
meta- analysis is possible, we will generate a pooled effect 
estimate for those exposed to long- term antibiotics and 
those unexposed within each category of study design. If 
there are a sufficient number of studies, subgroup anal-
yses will be undertaken, for example, by class of antibiotic 
and antibiotic treatment duration. The I2 statistic will be 
used to assess heterogeneity.23 Sources of heterogeneity 
may include methodology, age of participants, study 
duration, the confounding factors considered, the expo-
sure (ie, length/duration, the class of antibiotic), the 
comparators and the outcomes measured. If heteroge-
neity is above 50% we will not undertake a meta- analysis. 
If studies are sufficiently homogeneous with regard to 
exposures, comparators and outcomes, a random effects 
model will be used to generate a pooled relative risk and 
its 95% CI. Study characteristics and the effect estimate 
for the association between antibiotics for acne and the 
specific measure of AMR will be clearly presented. We will 
also do a sensitivity analysis using a fixed effects model. 
Publication bias will be assessed using Funnel plots and 
Egger tests.24 Forest plots will be presented. All statis-
tical analyses will be performed using Stata. If quanti-
tative synthesis is not possible due to heterogeneity, we 
will conduct a narrative synthesis. We will also study each 
category of outcome measure separately: for example, 
laboratory- based measures of resistance or outcome 
measures thought to be proxies for AMR using routinely 
collected health records. Given the breadth of outlined 
outcomes, it is likely that the evidence obtained will be 
diverse. An overall description of the strength of the body 
of evidence generated using GRADE will be described.21
The study will be reported following Preferred 
Reporting Items for Systematic Reviews and Meta- Analyses 
guidance.19
Patient and public involvement
This systematic review has been informed by the results 
of the Acne Priority Setting Partnership (PSP) ( acnepsp. 
org) in collaboration with the James Lind Alliance ( www. 
jla. nihr. ac. uk). Over 6000 responses were collated and 
voted on to give a top 10 list of treatment uncertainties. 
Two of these top 10 uncertainties will be addressed with 
this systematic review:
1. What is the correct way to use antibiotics in acne to 
achieve the best outcomes with the least risk?
2. What management strategy should be adopted for the 
treatment of acne in order to optimise short- term and 
long- term outcomes?
In addition, five people comprising members of the 
public and patients with acne or their carers will attend a 
focus group to help write the summary which will be used 
to disseminate the results of this systematic review to the 
public.
Ethics and dissemination
As this is a systematic review, ethical approval was not 
required. This systematic review protocol was registered 
on the 8th of April 2019 on the International Prospective 
Register of Systematic Reviews (PROSPERO). Any amend-
ments to the protocol will be updated and published on 
the PROSPERO website with clear notes of where specific 
changes were made with detailed explanations of why. 
The results of this systematic review will be submitted for 
peer- review publication.
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